Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efpegerglucagon/efpeglenatide - Hanmi Pharmaceutical

Next Previous
Drug Profile

Efpegerglucagon/efpeglenatide - Hanmi Pharmaceutical

Alternative Names: LAPSGlucagon combo; Glucagon combo - Hanmi Pharmaceutical; HM 11260C/HM 15136; HM-14320

Latest Information Update: 31 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihyperglycaemics; Antihypoglycaemics; Immunoglobulin Fc fragments; Obesity therapies; Pancreatic hormones; Peptides; Polyethylene glycols; Pyrrolidines; Recombinant proteins
  • Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Metabolic disorders; Obesity

Most Recent Events

  • 31 Jul 2024 Efpegerglucagon/efpeglenatide is still in preclinical trials for Obesity in South Korea (Hanmi Pharmaceutical pipeline, July 2024)
  • 31 Jul 2024 Preclinical trials in Metabolic disorders in South Korea (Parenteral) (Hanmi Pharmaceutical pipeline, July 2024).
  • 28 Feb 2023 No recent reports of development identified for preclinical development in Obesity in South Korea

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top